It is widely accepted that the sensitivity and specificity of serum enzymes and isoenzymes such as total creatine kinase (CK; EC 2.7.3.2), CK-MB activity, and lactate dehydrogenase, the final arbiters by which myocardial damage is diagnosed or excluded up to now, are inadequatle [1, 2] . Several new biochemical markers therefore have been investigated recently for the early and accurate diagnosis of acute myocardial infarction (AM!) [3] [4] [5] [6] . Because the contractile and regulatory proteins of the myocardium /7, 8] have high concentrations in myocytes and are expressed as tissue-specific isoforms, they appear to be potentially useful innovative biological markers for sensitive and specific diagnostic tests [9] [10] [11] .
In particular, troponin I (TnI), the inhibitory protein of the troponin-tropomyosin complex, has three isoforms, two skeletal and one cardiac (sTnI and cTnI respectively), that are encoded by three distinct genes, presenting a dissimilarity of -40% in the amino acid sequence [12] . Moreover, human cardiac TnT has 31 additional residues on its N-terminal end that are not present in skeletal forms, thus providing a high potential for obtaining cardiac-specific antibodies [13, 14] . Furthermore, since the molecular mass of human cardiac Tnl is 24 kDa, the protein is released fairly rapidly after AMI. This property and the unique amino acid sequence of cardiac TnI make it a promising candidate as a diagnostic marker for myocardial damage [15, 16] .
The aims of our study were therefore to evaluate the analytical performance of a fluoroenzymometric method previously proposed for cardiac TnI measurement [17] and compare its diagnostic accuracy with that of traditional markers of myocardial injury in the diagnosis and monitoring of patients with A?vH.
Materials and Methods

CLINICAL SPECIMENS
The study was carried out on 165 patients subdivided as follows: 
Group 4.
Patients with chronic skeletal muscle diseases (11), multiple traumas without chest contusion (6) , and with chronic renal failure (13) , to compare the clinical specificities of the tests in a worst-case situation.
In these patients the concomitant myocardial injury was excluded by the usual criteria,i.e.,no history of chest pain and no electrocardiographic signs of ischemia within the previous 3 weeks.
BLOOD SAMPLING
Only one blood sample was drawn from groups 1 and 4 patients. Blood samples were collected from AMI patients (group 2) immediately upon admission to the coronary care unit, and then hourly for the next 6 h, every 3 h until 24 h, and then every 6 h until the fourth day after admission.
In patients with unstable angina (group 3), the blood samples were collected at 4-h intervals during the first 24 h and at 6-h intervals until 2 days after hospitalization, whereas in patients with chest pain and stable angina (group 3), one blood sample only was drawn. Then, by plotting the sensitivity vs 1 -specificity, receiver-operating characteristic (ROC) curves were constructed to compare the discriminative power of the methods tested. The diagnostic efficiency was ascertained on the basis of the area under the ROC curve. Areas under the curves and differences between ROC curves were calculated according to the method proposed by Hanley and McNeil [25, 26] 
Results
The TnI assay evaluated in our study ( In healthy subjects TnI concentrations had a skewed distribution, ranging from 0 to 0.3 p.gfL; >99% of values were lower than the detection limit of the assay. The TnI concentrations observed in all patients studied and expressed as median, 10%, and 90% are reported in Table 2 .
With the exception of AM! and unstable angina patients, cardiac
TnT could not be detected by this assay in other patients studied.
In seven patients with unstable angina (classIII and class II), detectable amounts of TnT without significant variations during monitoring were observed. In our patients, no cardiac events during the hospitalization and during the monitoring were clinically diagnosed, even in the patient with the highest value of TnT (0.9 .tgfL).
A graphic test evaluation of the TnI assay in AM! is presented in Fig. 1. In Fig. 1A , the double histogram compares the frequency distributions of TnT values observed 4 h after onset of chest pain in AM! cases (group 2, upper field) with those obtained in group 3 subjects (lower field), arranged in 10 nonequidistant classes,ranging from 0 to 30 .tg/L. The sensitivity and specificity curves are a function of the test value and reflect different distributions.
On the basis of these curves, a discriminator value of 1 .tg/L yields a sensitivity of 0.769 and a specificity of 1.0 with a diagnostic efficiency of 0.943. For evaluating the clinical specificity under worst-case situations, we replotted the TnI data of AMI cases (Fig. 1B, upper field) in 
1B, lower field). No difference in the clinical specificity of the
TnT assay was observed in two clinical conditions considered. The performances of all markers considered in our study were calculated in the described population with the same approach (Table  3) . During the first 4 h after onset of chest pain, myoglobin showed the highest sensitivity, followed by CK-MB and TnI, whereas total CK was significantly less sensitive. On the other hand, during -3 days of monitoring, we observed for all tests a time-dependent sensitivity (Fig. 2) . In particular, during the first 2 h after the onset of symptoms, myoglobin showed the highest sensitivity (1.0), while those of total CK, CK-MB, and Tn! were -0.60. The maximum value of sensitivity (1.0) was observed from 7 to 24 h for CK-MB and from 10 to 21 h for total CK. Tn! showed a constantly high sensitivity (1.0) from the 10th hour forward, while, as expected, those of the other markers progressively decreased, being 0.20 (myoglobin), 0.37 (CK-MB), and 0.62 (total CK) 70 h after the onset of symptoms.
Furthermore, the clinical specificity of all markers studied, except that of TnT, decreased markedly if the evaluation was carried out in a worst-case situation, i.e., in patients with concomitant skeletal or renal diseases.
In another approach for assessing the diagnostic efficiency of TnT compared with that of the traditional biochemical AM! markers considered in our study, ROC curves were generated (Fig. 3) . Despite minor differences, the area under the TnT ROC curve (0.932; 95% confidence interval 0.83-1.0) was almost the same as the unit area under the CK-MB curve (0.956; 95% confidence interval 0.87-1.0) and total CK (0.920; 95% confidence interval 0.81-1.0), showing no significant difference in comparison with the ROC curve for myoglobin (0.960; 95% confidence interval 0.88-1.0), the last being the most useful marker in diagnosing myocardial infarction within 4 h after the onset of chest pain (Fig. 3A) . On the other hand, in patients with concomitant skeletal muscle damage or with renal diseases ( The release kinetics, and the relative increase in values of markers studied in AM! patients, are summarized in Table 4 . The first increased value in Tn! concentrations after infarction (interquartile range 3.25-6.0 h) and the peak (interquartile range 11.5-24.0 h) occurred later than in myoglobin and in CK-MB concentrations, but increased serum TnI concentrations persisted much longer (>96 h). Furthermore, serum TnT concentrations exceeded the discriminator limit by >158-fold.
The pattern of serum TnT release in AM! patients shows a monophasic time-dependent kinetic (Fig. 4, upper field) . A marked increase in serum TnI was observed on day 1, resulting in a median peak value at -40 times the discriminator limit at a median time of 18 h after the onset of pain. The initially released
TnT was rapidly eliminated from the circulation, and a long plateau effect was observed from the second to the fourth day after onset of symptoms when TnT concentrations were persistently -threefold the discriminator limit. Changes in TnT were similar to those of CK-MB (Fig. 4 , lower field), the most striking difference being the long release of TnT, the concentrations of which remained increased >96 h after onset of chest pain. The prolonged serum increase of this marker provided a diagnostic window from 10 to at least 96 h after onset of pain, during which TnT was detectable in all serum samples of all patients. In our cases the pattern of its release in AM! patients was not influenced by reperfusion of the infarct-related artery, being monophasic in all patients.
rnscussion
Our findings demonstrate that the fluoroenzymometric method for TnT assay has a good analytical performance.
The evaluated assay, commercially available, uses the same antibodies originally developed by Bodor et al. [17] , and extensively reported in experimental studies [28, 29] . The relation between the current assay and the research method calculated by the weighted least-squares equation is 0.211 (research assay)-0.0l9 (Ladenson JH, Division of Laboratory Medicine, Washington University, St. Louis, MO, personal communication).
Thus, previously reported cutoff values cannot be taken into consideration using the commercial procedure. We found that Tn! has several advantages over traditional Table 3 . DIagnostIc performances (and 95% confidence Intervals) of bIochemIcal markers for AMI 4 h after onset of chest paIn. 
the content of free cytoplasmic pool of TnT being lower than that reported for TnT (-3% vs 6%, respectively) [28] . Nevertheless, this finding must be confirmed in a larger population because the results reported in the literature by different authors are contradictory [31, 35] . In a larger population, the diagnostic potential of the TnI assay for detecting minor myocardial damages should also be verified; no conclu- Hours after the onset of chest pain Ag. 2. Diagnostic sensitivity of mnl, total CK activity, CK-MB mass concentration, and myoglobin in relationto hours after onset of AMI symptoms.
serological markers of myocardial injury, the greatest one being its cardiospecificity [30] . TnI measurement is therefore particularly helpful in the assessment of patients with myocardial ischemia and skeletal muscle damage [31, 32] . Tn! results are also easy to interpret because serum concentrations are usually very low (between 0 to 0.3 j.g/L) and increase substantially (up to 158 times the discriminator) in response to an acute infarction. At the decisional concentration for AM! chosen in our study, 1 g/L, the assay shows a good diagnostic efficiency (0.943) with an excellent clinical specificity (1.0), even in patients in whom traditional biochemical markers of AMI are adversely influenced by diverse underlying clinical situations [32, 33] . Tn fact, in clinical pratice it is necessary to rule out AM! not only in patients with angina and other heart diseases, but also in patients with muscular or renal diseases admitted to the hospital with aspecific symptoms.
Despite its structural localization, in AM!, TnT appears in the circulation within a few hours after the onset of chest pain [34] , and high concentrations persist for at least 4 days [35] . This sustained increase in the serum concentrations probably reflects a continuing release of this protein from disintegrating myofilaments; consequently there is a long diagnostic window, from 10 to at least 96 h after onset of pain, during which the TnT concentration exceeded the discriminator limit for AM! in all serum samples of our patients. This release pattern, in common with that of other contractile proteins, increases the likelihood of a positive test result, particularly in the subacute phase of infarction [8, 9] .
The serum release kinetic observed for Tn! in our study was monophasic in all patients studied, irrespective of the outcome of thrombolytic treatment. This behavior, different from that observed in some studies for other structural proteins such as troponin T (TnT) [9, 11] , may suggest that the rapid loss of the cytoplasmic pool was superimposed on prolonged myofibrillar sion, in fact, can be drawn from our data, being too limited in the number of patients with angina. Our results confirm that TnT measurement is a substantial advance in the laboratory diagnosis and monitoring of AM!, and is of particular value because a rapid and automated Tn! determination is now available. The high analytical sensitivity of the current method, its turnaround time, and the practicability enabled us to detect cardiac TnT very early after A1vII, in an emergency situation.
a. The unique properties of this protein and, in particular, its high diagnostic specificity (1.0) and sensitivity in the early phase of AMI (0.769 during 0-4 h after onset of pain), the high concentration gradient between myocardial cells and normal blood, and the stability and rate of elimination suggest that the Tn! measurements could become a valuable differential diagnostic tool to investigate myocardial damage in emergency room patients, even in cases of concomitant skeletal muscle injury, as occurs in polytraumatized patients. Tn fact, as reported in our study, the measurement of the traditional markers in these patients is ineffectual because of its lack of specificity. In our experience myoglobin remains the more sensitive marker in the earlier phases of AM!. Differences in the sensitivity of this marker described in the literature [34, 36, 37] can be attributed to the lack of standardization and optimization of methods used for its measurement.
In conclusion, the determination of TnT in combination with myoglobin, the earlier marker of myocardial damage, allows a reliable and timely diagnosis to be made; myocardial necrosis to be ruled out in patients with renal failure [33] or with skeletal muscle myopathies; and the course of myocardial damage to be monitored during therapy.
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